Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell of lymphatic vessel | 21 studies | 44% ± 15% | |
endothelial cell | 8 studies | 24% ± 6% | |
capillary endothelial cell | 4 studies | 19% ± 4% | |
glomerular endothelial cell | 3 studies | 22% ± 1% |
Insufficient scRNA-seq data for expression of FLT4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 8876.83 | 653 / 653 | 95% | 12.28 | 572 / 605 |
adrenal gland | 100% | 3264.53 | 258 / 258 | 94% | 11.26 | 216 / 230 |
breast | 100% | 4854.97 | 459 / 459 | 92% | 5.78 | 1032 / 1118 |
lung | 100% | 5507.71 | 578 / 578 | 86% | 5.75 | 988 / 1155 |
kidney | 100% | 5275.74 | 89 / 89 | 83% | 21.56 | 748 / 901 |
esophagus | 95% | 1581.98 | 1372 / 1445 | 85% | 4.78 | 155 / 183 |
prostate | 98% | 1940.18 | 241 / 245 | 69% | 2.88 | 344 / 502 |
bladder | 100% | 1775.71 | 21 / 21 | 64% | 3.01 | 324 / 504 |
liver | 76% | 987.15 | 171 / 226 | 81% | 4.44 | 327 / 406 |
intestine | 92% | 1674.48 | 892 / 966 | 62% | 2.98 | 329 / 527 |
ovary | 79% | 1322.41 | 142 / 180 | 73% | 4.07 | 315 / 430 |
uterus | 99% | 3135.01 | 169 / 170 | 50% | 2.58 | 228 / 459 |
stomach | 73% | 825.28 | 262 / 359 | 74% | 4.27 | 211 / 286 |
skin | 59% | 807.47 | 1071 / 1809 | 63% | 3.45 | 298 / 472 |
pancreas | 18% | 145.33 | 60 / 328 | 93% | 5.61 | 165 / 178 |
brain | 28% | 392.56 | 737 / 2642 | 82% | 4.66 | 579 / 705 |
adipose | 100% | 4536.15 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 5508.88 | 241 / 241 | 0% | 0 | 0 / 0 |
heart | 88% | 1152.92 | 756 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 62% | 2.46 | 18 / 29 |
tonsil | 0% | 0 | 0 / 0 | 58% | 2.46 | 26 / 45 |
blood vessel | 47% | 714.77 | 624 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 39% | 1.16 | 31 / 80 |
muscle | 37% | 272.01 | 299 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 4% | 30.78 | 41 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0060312 | Biological process | regulation of blood vessel remodeling |
GO_0001525 | Biological process | angiogenesis |
GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0010595 | Biological process | positive regulation of endothelial cell migration |
GO_0007275 | Biological process | multicellular organism development |
GO_0001946 | Biological process | lymphangiogenesis |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0038084 | Biological process | vascular endothelial growth factor signaling pathway |
GO_0002040 | Biological process | sprouting angiogenesis |
GO_0033674 | Biological process | positive regulation of kinase activity |
GO_0001944 | Biological process | vasculature development |
GO_0018108 | Biological process | peptidyl-tyrosine phosphorylation |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0001938 | Biological process | positive regulation of endothelial cell proliferation |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0003016 | Biological process | respiratory system process |
GO_0010575 | Biological process | positive regulation of vascular endothelial growth factor production |
GO_0090037 | Biological process | positive regulation of protein kinase C signaling |
GO_0048010 | Biological process | vascular endothelial growth factor receptor signaling pathway |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0048514 | Biological process | blood vessel morphogenesis |
GO_0043408 | Biological process | regulation of MAPK cascade |
GO_0001945 | Biological process | lymph vessel development |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0035924 | Biological process | cellular response to vascular endothelial growth factor stimulus |
GO_0048286 | Biological process | lung alveolus development |
GO_0043235 | Cellular component | receptor complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0005021 | Molecular function | vascular endothelial growth factor receptor activity |
GO_0019903 | Molecular function | protein phosphatase binding |
GO_0004714 | Molecular function | transmembrane receptor protein tyrosine kinase activity |
GO_0019838 | Molecular function | growth factor binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FLT4 |
Protein name | Fms related receptor tyrosine kinase 4 (Soluble VEGFR3 variant 2) Vascular endothelial growth factor receptor 3 variant (EC 2.7.10.1) Fms-related tyrosine kinase 4 (EC 2.7.10.1) Alternative protein FLT4 Vascular endothelial growth factor receptor 3 (EC 2.7.10.1) Vascular endothelial growth factor receptor 3 Vascular endothelial growth factor receptor 3 (VEGFR-3) (EC 2.7.10.1) (Fms-like tyrosine kinase 4) (FLT-4) (Tyrosine-protein kinase receptor FLT4) |
Synonyms | VEGFR3 |
Description | FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'. . |
Accessions | A0A0A7DZ98 A0A0A7DZ95 ENST00000512795.1 A0A0A7DZ60 I6ZMK4 A0A0H4A7R5 ENST00000393347.7 [P35916-1] A0A0H4A774 A0A0A7DYC7 ENST00000502649.5 ENST00000619105.4 B5A927 A0A0A7DYE1 P35916 A0A0H4ADY2 A0A0A7DYA9 A0A0H4ABZ1 I6ZVY0 I6YRR9 A0A097NUS3 A0A0H4A771 ENST00000261937.11 [P35916-2] A0A0H4AF71 E9PD35 D6RFF2 L8EBH4 |